When is the best time to screen and evaluate for treatable genetic disorders?: A lifespan perspective

Author:

Parisi Melissa A.1ORCID,Caggana Michele2,Cohen Jennifer L.3,Gold Nina B.4,Morris Jill A.5ORCID,Orsini Joseph J.6,Urv Tiina K.7ORCID,Wasserstein Melissa P.8

Affiliation:

1. Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda Maryland USA

2. Wadsworth Center, New York State Department of Health Division of Genetics Albany New York USA

3. Duke University School of Medicine Durham North Carolina USA

4. Massachusetts General Hospital for Children Boston Massachusetts USA

5. National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda Maryland USA

6. New York State Department of Health Wadsworth Center Albany New York USA

7. National Center for Advancing Translational Sciences National Institutes of Health Bethesda Maryland USA

8. Albert Einstein College of Medicine and the Children's Hospital at Montefiore Bronx New York USA

Abstract

AbstractThis paper focuses on the question of, “When is the best time to identify an individual at risk for a treatable genetic condition?” In this review, we describe a framework for considering the optimal timing for pursuing genetic and genomic screening for treatable genetic conditions incorporating a lifespan approach. Utilizing the concept of a carousel that represents the four broad time periods when critical decisions might be made around genetic diagnoses during a person's lifetime, we describe genetic testing during the prenatal period, the newborn period, childhood, and adulthood. For each of these periods, we describe the objectives of genetic testing, the current status of screening or testing, the near‐term vision for the future of genomic testing, the advantages and disadvantages of each approach, and the feasibility and ethical considerations of testing and treating. The notion of a “Genomics Passbook” is one where an early genomic screening evaluation could be performed on each individual through a public health program, with that data ultimately serving as a “living document” that could be queried and/or reanalyzed at prescribed times during the lifetime of that person, or in response to concerns about symptoms of a genetic disorder in that individual.

Publisher

Wiley

Subject

Genetics (clinical),Genetics

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation;International Journal of Neonatal Screening;2024-01-17

2. Genomic newborn screening for rare diseases;Nature Reviews Genetics;2023-06-29

3. Note from the editors;American Journal of Medical Genetics Part C: Seminars in Medical Genetics;2023-03

4. The Rare Diseases Clinical Research Network: a model for clinical trial readiness;Therapeutic Advances in Rare Disease;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3